Granulin as a Target for Tumor Diagnosis and Growth Regulation
The new method selects gene products that are actually translated from mRNA species. Antibodies to clones of interest can be generated for antibody-based studies.
Identification of gene products that are differentially expressed in tumors Detection and monitoring of cancers overexpressing GranulinDevelopment of therapeutics for nervous system cancer based on inhibition of granulin DTreatment of cancers overexpressing GranulinCancer vaccines based on Granulin antigens
Researchers at the University of California have developed a new method for identifying differentially expressed gene products that are translated from mRNA species. This method, termed differential immuno-absorption (DIA), uses subtractive antibody-based screening of target versus control tissues followed by screening of a cDNA expression library to identify differentially expressed proteins. DIA can be coupled to cDNA microarray hybridization and used in the identification of genes that play a role in the malignant progression of cancer. Using this method, the researchers identified a putative growth factor gene, granulin D, which may play a role in the malignant progression of glioblastomas. The researchers determined that granulin D stimulates growth of glial cells in vitro. In addition, antibodies to granulin D inhibit growth of early-passage human brain tumor cell cultures in vitro. Thus, inhibition of granulin D could be of clinical importance.
Patent Number: US6558668B2
Application Number: US2001795714A
Inventor: Liau, Linda M.
Priority Date: 28 Feb 2000
Priority Number: US6558668B2
Application Date: 28 Feb 2001
Publication Date: 6 May 2003
IPC Current: A61K003900 | C07K001618 | C12N000502 | C12N000508 | C12N001510 | G01N0033574
US Class: 4241741 | 435455
Assignee Applicant: The Regents of the University of California
Title: Methods for detection and treatment of neural cancers
Usefulness: Methods for detection and treatment of neural cancers
Summary: For identifying proteins differentially expressed in a target tissue, especially neural tissue. Proteins identified in this way, e.g., granulin may be used as targets for molecules (especially antibodies, antisense nucleotides, or granulin peptide) which disrupt their activity for the treatment of cancer of the nervous system comprising glioblastoma, astrocytoma, oligodendroglioma, ependymoma, choroids plexus papilloma, medulloblastoma, Schwannoma, neurofibroma, or neurilemmoma, where the cancer is associated with a neuronal, pineal or pituitary tumor (all claimed).
Novelty: Identifying differentially expressed gene products that are translated from mRNA species comprises differential immuno-absoprtion and antibody-based screening of a cDNA expression library
診斷/治療
癌症/腫瘤
6558668
BACKGROUND Cancer is the result of cumulative multiple genetic mutations, which result in the activation of oncogenes and/or the inactivation of tumor suppressor genes. It is the differential expression of these critical genes and their downstream effectors that enables cells to override growth controls and undergo carcinogenesis. While a variety of methods are currently employed to isolate genes associated with particular differential phenotypes, these techniques identify tissue-enriched mRNAs rather than tissue-specific proteins. Thus, there remains a need for a differential screening technique that provides actual confirmation of the presence of a protein product, not just the capacity to synthesize a protein. In addition, there is a need for proteins with antigenic determinants that may be recognized by the immune system. Related Materials Additional Technologies by these Inventors Tech ID/UC Case 10174/2000-236-0 Related Cases 2000-236-0
美國
